Results from Alliance CABOSUN trial lead to US FDA approval of extended indication

December 20, 2017, Alliance for Clinical Trials in Oncology

The Alliance for Clinical Trials in Oncology (the Alliance), in conjunction with industry partner Exelixis, today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX (cabozantinib) tablets for the expanded indication of patients with advanced renal cell carcinoma (RCC). RCC is the most common form of kidney cancer in adults. The FDA's priority review and approval of cabozantinib was based on results from the Alliance randomized phase II CABOSUN trial in patients with previously untreated RCC, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus sunitinib, a current standard of care. Today's label expansion follows the initial FDA approval of cabozantinib in April 2016 for the treatment of patients with advanced RCC who have previously received anti-angiogenic therapy.

"The CABOSUN trial enrolled treatment-naïve with advanced , including those who are known to fare poorly, such as patients with intermediate- or poor-prognostic factors and those with bone metastases or multiple sites of metastatic disease," said Toni Choueiri, MD, Director, Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute and chair of the CABOSUN study. "Physicians are already experienced in using cabozantinib in the second-line advanced RCC setting, and it is a much-needed advance to also now have cabozantinib as an option for their patients with previously untreated advanced RCC."

The expanded approval of cabozantinib is based on results of the phase II CABOSUN trial, which met its primary endpoint of improving PFS. According to the independent radiology review committee analysis of the data, cabozantinib demonstrated a clinically meaningful and statistically significant 52 percent reduction in the rate of disease progression or death (HR 0.48, 95% CI 0.31-0.74, two-sided P=0.0008). Median PFS for cabozantinib was 8.6 months versus 5.3 months for sunitinib, corresponding to a 3.3-month (62 percent) improvement.

All causality Grade 3 or 4 adverse reactions occurred in 68 percent of patients receiving cabozantinib and 65 percent of patients receiving sunitinib. The most frequent all causality Grade 3-4 adverse reactions (less than or equal to 5 percent) in patients treated with cabozantinib were hypertension, diarrhea, hyponatremia, hypophosphatemia, palmar-plantar erythrodysesthesia (PPE), fatigue, increased ALT, decreased appetite, stomatitis, pain, hypotension, and syncope. Twenty-one percent of patients in the cabozantinib arm compared to 22 percent of patients receiving sunitinib discontinued treatment due to adverse events.

"We at the Alliance are very gratified that the CABOSUN study supported the approval of cabozantinib for the potential first-line treatment of all patients with advanced . This trial exemplifies how NCI-sponsored studies can be efficient, accrue rapidly, and yield results highly relevant to the field," said Michael J. Morris, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, and Chair of the Alliance Genitourinary (GU) Committee.

Explore further: New drug beats standard therapy in advanced kidney cancer

Related Stories

New drug beats standard therapy in advanced kidney cancer

November 15, 2016
An experimental kidney cancer drug outperformed the standard first-line therapy for patients with metastatic disease who are considered at risk for poorer than average outcomes, according to results of a randomized phase ...

Cabozantinib improves progression-free survival in metastatic renal cell carcinoma

October 10, 2016
Cabozantinib significantly improves progression-free survival and response rate in patients with metastatic renal cell carcinoma compared to sunitinib, according to research presented today at the ESMO 2016 Congress in Copenhagen.

ASCO: Cabozantinib improves progression-free survival in RCC

January 5, 2016
(HealthDay)—For patients with advanced renal cell carcinoma, cabozantinib is associated with improved progression-free survival (PFS), with consistent improvement across all patient subgroups, according to a study scheduled ...

New drug improves outcome in treatment resistant kidney cancer

September 28, 2015
A new drug has been found superior to current treatments in slowing the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had kept it in check, according to results from a ...

Cabozantinib active in castration-resistant prostate cancer

December 3, 2012
(HealthDay)—The orally bioavailable tyrosine kinase inhibitor cabozantinib (XL184) has clinical activity in men with castration-resistant prostate cancer (CRPC), according to a study published online Nov. 19 in the Journal ...

Cabozantinib improves survival in patients with advanced kidney cancer

September 25, 2015
Vienna, Austria: Patients with advanced kidney cancer live for nearly twice as long without their disease progressing if they are treated with cabozantinib, a drug that inhibits the action of tyrosine kinases - enzymes that ...

Recommended for you

Researchers discover new anti-cancer protein

March 21, 2018
An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from ...

Targeting telomeres to overcome therapy resistance in advanced melanoma

March 21, 2018
A study conducted at The Wistar Institute in collaboration with The University of Texas Southwestern Medical Center has demonstrated the efficacy of targeting aberrantly active telomerase to treat therapy-resistant melanoma. ...

Cancer comes back all jacked up on stem cells

March 19, 2018
After a biopsy or surgery, doctors often get a molecular snapshot of a patient's tumor. This snapshot is important - knowing the genetics that cause a cancer can help match a patient with a genetically-targeted treatment. ...

Researchers create a drug to extend the lives of men with prostate cancer

March 16, 2018
Fifteen years ago, Michael Jung was already an eminent scientist when his wife asked him a question that would change his career, and extend the lives of many men with a particularly lethal form of prostate cancer.

Machine-learning algorithm used to identify specific types of brain tumors

March 15, 2018
An international team of researchers has used methylation fingerprinting data as input to a machine-learning algorithm to identify different types of brain tumors. In their paper published in the journal Nature, the team ...

Higher doses of radiation don't improve survival in prostate cancer

March 15, 2018
A new study shows that higher doses of radiation do not improve survival for many patients with prostate cancer, compared with the standard radiation treatment. The analysis, which included 104 radiation therapy oncology ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.